Vera Therapeutics said its recently approved IgA nephropathy therapy, Trutakna, delivered final two-year Phase 3 results, including stabilization of kidney function and a reduced risk of kidney-related death and complications. The company said it will pursue full FDA approval during the fourth quarter following the durability readout. The reporting ties back to an accelerated approval granted in July, now supported by longer follow-up. For clinicians and payers, the shift from accelerated to full approval path signals an effort to convert early benefit into a broader label. The update reinforces the importance of long-term endpoints in renal immunology programs and could affect treatment selection and reimbursement as Vera prepares its next FDA submission.